What is this medicine used for?
FDA-approved uses
- Maintenance of abstinence from alcohol in alcohol dependence — Adults who have completed withdrawal and are abstinent at treatment initiation. Used with psychosocial support. Benefit has not been demonstrated when treatment begins without detoxification and abstinence.acamprosate calcium delayed-release tablets.
What should I expect?
The goal is to support continued days without alcohol, rather than produce an immediately noticeable feeling. Review drinking, cravings, side effects, and recovery support with the care team; there is no reliable single-day test of whether it will help.
Agree on a follow-up plan when treatment starts. Contact the prescriber if symptoms worsen, side effects disrupt daily life, or there is no useful improvement by the planned review; do not change the dose yourself.
How do I take it safely?
Swallow delayed-release tablets whole; do not split, crush, or chew. Treatment is usually taken three times daily, with or without food, after withdrawal has been managed and abstinence achieved. Regular meals can help you remember.
Kidney function must be assessed. Moderate impairment requires a lower prescribed dose; severe impairment (the label’s creatinine clearance of 30 mL/min or less) rules out use. Tell the pharmacist about sulfite sensitivity and check the actual product ingredients.
Severe kidney impairment: labeled creatinine clearance of 30 mL/min or less. Known allergy to acamprosate calcium or formulation ingredients.
Keep follow-up for mood, suicidal thoughts, drinking, and recovery support alongside treatment.
Acamprosate has limited metabolism-related interactions because it is not broken down by liver CYP enzymes. The selected label found no clinically important interaction with naltrexone requiring dose adjustment, but that is not a recommendation to combine them yourself. The absence of a disulfiram-like reaction does not make drinking safe or remove the need to discuss relapse with the care team. Review all medicines and supplements, including those that may affect kidney function.
Adequate controlled pregnancy studies are lacking; the label recommends use only when the potential benefit justifies fetal risk. Alcohol exposure itself can harm pregnancy, so treatment planning should address both concerns. Human milk transfer is unknown in the selected label, and breastfeeding requires an individualized discussion.
Pediatric safety and effectiveness are not established. Few older adults were included in trials; declining kidney function can increase exposure and makes dose selection and renal assessment particularly important.
If a dose is missed, follow the pharmacist’s instructions; skip it when nearly time for the next dose and never double it. The label advises continuing prescribed treatment after a return to drinking and telling the clinician, so the recovery plan can be reassessed. Acamprosate is not associated with a withdrawal syndrome in the clinical trials, but decisions about stopping should consider ongoing recovery needs.
What side effects should I know about?
- Diarrhea, gas, nausea or lower appetite.
- Dizziness, anxiety, itching or sweating can occur.
Tell your prescriber about effects that are persistent, troublesome, or interfere with daily life.
Looking for more detailed information?
The official medicine information lists more side effects, safety advice and product instructions.
- View FDA Prescribing Information (PDF) (opens in a new tab)Acamprosate delayed-release tablets (Zydus labeling)
Which warning signs need help?
- New suicidal thoughts or major mood deterioration need prompt help; immediate danger requires emergency care.
- Severe allergic swelling or breathing trouble requires emergency assessment.
- Confusion, hallucinationsHallucinationsA hallucination is a sensory experience without a corresponding external source—for example, hearing a voice when nobody is speaking. It can involve hearing, sight, touch, smell or taste and may feel very real.A hallucination is an experience; a delusion is a belief. Hallucinations can have different causes, so an assessment is needed to understand them. or seizures during alcohol withdrawal require urgent treatment; acamprosate does not treat withdrawal.
What else should I know to stay safe?
- Do not use with a product allergy or severe kidney impairment. Kidney function must be assessed: moderate impairment requires a lower prescription, while a creatinine clearance of 30 mL/min or less rules out use. Check the actual ingredients if you have sulfite sensitivity.
- Use with counseling and recovery support. Acamprosate does not treat alcohol withdrawal and is started after abstinence is achieved. If drinking resumes, tell the care team; the label advises continuing prescribed treatment while the recovery plan is reviewed. Keep mood and recovery follow-up, and have other medicines checked, especially those affecting kidney function.
- Discuss pregnancy and breastfeeding because human evidence is limited; alcohol exposure itself also matters. Pediatric effectiveness is not established. Older adults need particular attention to kidney function and medicine exposure.
Urgent help and crisis support · Emergency & Crisis Resources (US)
What can help day to day?
- Regular mealtimes can serve as reminders for the three daily doses, even though food is optional.
- If you return to drinking, tell the care team. The label advises continuing prescribed acamprosate while the recovery plan is reassessed; a lapse is a reason for support, not a reason to improvise treatment changes.
How does it work?
Acamprosate appears to influence communication between brain cells after prolonged alcohol exposure. Researchers do not yet know exactly which changes explain its ability to help some people maintain abstinence, meaning a period without drinking. The main explanation concerns systems that increase or restrain nerve-cell activity.
How was this medicine developed?
The FDA approved Campral in 2004. The studies supporting approval paired the medicine with psychosocial treatment in people already abstinent after detoxification. That context explains why acamprosate is a recovery support rather than a withdrawal treatment.
How do I say the name?
Acamprosate: uh-KAM-proh-sayt. Capital letters show the stressed syllable.
Sources and References
Sources support the U.S. products described here. Product instructions can differ; use the information supplied with your own medicine.
- Acamprosate calcium delayed-release tablets: current generic prescribing information
- Acamprosate: patient information
- Campral: FDA approval and discontinued product record
- Campral: FDA reference prescribing information
- Acamprosate: Package Insert / Prescribing Information / MOA
- DailyMed - ACAMPROSATE CALCIUM tablet, delayed release
- Acamprosate calcium: FDA generic application record
- Naltrexone: prescribing information
- SAMHSA TIP 49: acamprosate (2009 background guidance)
- Schizophrenia
- NIMH: Understanding psychosis
Giving medicine safely to children: family guide (PDF, 3 pages)

